Breaking News

Japan's October Industrial Production Rises 0.2%
Tweet TWEET

Acura Pharmaceuticals Awarded U.S. Patent for Abuse Deterrent Drug Formulations

Acura Pharmaceuticals Awarded U.S. Patent for Abuse Deterrent Drug Formulations 
Further Expands Patent Estate Covering Abuse Deterrent Forms of
Opioid Analgesics and Certain Other Active Pharmaceutical Ingredients 
PALATINE, IL -- (Marketwired) -- 04/04/13 --  Acura Pharmaceuticals,
Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating
abuse deterrent drugs, today announced that the company has been
issued U.S. Patent No. 8,409,616 by the United States Patent and
Trademark Office.  
Claims in the patent cover, among other inventions, Acura's AVERSION
polymer matrix technology when utilized with any water soluble drug
of abuse. The opioid products being developed by Acura are covered by
this patent. Also, certain claims in this patent are licensed to
Pfizer Inc. (NYSE: PFE) which utilizes the AVERSION technology in its
Oxecta(R) (oxycodone HC
l) tablets CII. 
This is the fourth issued U.S. patent directed at products developed
with the AVERSION technology.  
About Acura Pharmaceuticals
 Acura Pharmaceuticals is a specialty
pharmaceutical company engaged in the research, development and
commercialization of product candidates intended to address
medication abuse and misuse, utilizing its proprietary AVERSION(R)
and IMPEDE(TM) technologies. AVERSION contains polymers that cause
the drug to gel when dissolved; it also contains compounds that
irritate the nasal passages. IMPEDE is designed to disrupt the
processing of pseudoephedrine from tablets into methamphetamine. 
In June 2011, the U.S. Food and Drug Administration approved
OXECTA(R) (oxycodone HC1 tablets) which incorporates the AVERSION(R)
technology. The Company has a development pipeline of additional
AVERSION(R) technology products containing other opioids.  
In December 2012, the Company commenced commercialization of
Nexafed(R) [pseudoephedrine hydrochloride (HCl)], a 30 mg
immediate-release abuse-deterrent decongestant. The next generation
pseudoephedrine tablet combines effective nasal congestion relief
with IMPEDE(TM) technology, a unique polymer matrix that disrupts the
conversion of pseudoephedrine into the dangerous drug,
methamphetamine.  
The trademark OXECTA(R) is owned by Pfizer Inc. 
Forward-Looking Statements
 Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forwarding-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance, or achievements expressed or implied by
such forward-looking results, performance, or achievements expressed
or implied by such forward-looking statements. Forward-looking
statements may include, but are not limited to, our ability to raise
capital under the shelf registration statement from the sale of our
securities, our and our licensee's ability to successfully launch and
commercialize our products and technologies including Oxecta(R)
Tablets and Nexafed(R) Tablets, the price discounting that may be
offered by Pfizer for Oxecta(R), our and our licensee's ability to
obtain necessary regulatory approvals and commercialize products
utilizing our technologies and the market acceptance of and
competitive environment for any of our products, the willingness of
wholesalers and pharmacies to stock Nexafed Tablets, expectations
regarding potential market share for our products and the timing of
first sales, our ability to enter into additional license agreements
for our other product candidates, our exposure to product liability
and other lawsuits in connection with the commercialization of our
products, the increased cost of insurance and the availability of
product liability insurance coverage, the ability to avoid
infringement of patents, trademarks and other proprietary rights of
third parties, and the ability of our patents to protect our products
from generic competition, our ability to protect and enforce our
patent rights in any paragraph IV patent infringement litigation, and
the ability to fulfill the FDA requirements for approving our product
candidates for commercial manufacturing and distribution in the
United States, including, without limitation, the adequacy of the
results of the laboratory and clinical studies completed to date, the
results of laboratory and clinical studies we may complete in the
future to support FDA approval of our product candidates and the
sufficiency of our development to meet over-the-counter, or OTC,
Monograph standards as applicable, the adequacy of the development
program for our product candidates, including whether additional
clinical studies will be required to support FDA approval of our
product candidates, changes in regulatory requirements, adverse
safety findings relating to our product candidates, whether the FDA
will agree with our analysis of our clinical and laboratory studies
and how it may evaluate the results of these studies or whether
further studies of our product candidates will be required to support
FDA approval, whether or when we are able to obtain FDA approval of
labeling for our product candidates for the proposed indications and
will be able to promote the features of our abuse discouraging
technologies, whether our product candidates will ultimately deter
abuse in commercial settings and whether our Impede technology will
disrupt the processing of pseudoephedrine into methamphetamine. In
some cases, you can identify forward-looking statements by terms such
as "may," "should," "could," "would," "expects," "plans,"
"anticipates," "believes," "estimates," "projects," "predicts,"
"potential" and similar expressions intended to identify
forward-looking statements. These statements reflect our current
views with respect to future events and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
We discuss many of these risks in greater detail in our filings with
the Securities and Exchange Commissi
on. 
Contact: 
for Acura Investor Relations
investors@acurapharm.com
847-705-7709 
for Acura Media Relations
pr@acurapharm.com
847-705-7709 
 
 
Press spacebar to pause and continue. Press esc to stop.